Abstract
PD-1 inhibitors show efficacy in hepatocellular carcinoma (HCC), yet overall outcomes remain poor. In this retrospective study of 258 advanced HCC patients treated between 2019 and 2024, peripheral blood B-cell dynamics were evaluated. Patients with higher B-cell proportions or absolute counts had significantly longer overall survival (OS) and progression-free survival (PFS). Multivariate analysis confirmed elevated B-cell proportion as an independent protective factor for OS. These results suggest that peripheral blood B-cell levels may serve as prognostic biomarkers for PD-1-based immunotherapy in advanced HCC.
Affiliated Institutions
Related Publications
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). K...
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
3016 Background: The immune checkpoint receptor programmed death-1 (PD-1) negatively regulates T-cell activation. In a phase I study, nivolumab, a PD-1 receptor blocking antibod...
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Purpose To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carc...
Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third of patients eligible for curative treatments and very limited survival benefits with the use of...
Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation
The growth rates of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLTX) were estimated by calculating the tumor doubling time (TDT) in 20 pati...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Jing Tang,
Yujing Mo,
Na Wu
(2025).
Changes in peripheral blood B cell levels predict overall survival in patients with advanced liver cancer treated with immune target inhibitors.
Discover Oncology
.
https://doi.org/10.1007/s12672-025-04236-x
Identifiers
- DOI
- 10.1007/s12672-025-04236-x